Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2009) 20 P363

ECE2009 Poster Presentations Diabetes and Cardiovascular (103 abstracts)

Chemotherapy does not influence measures of glycaemic control in non-diabetic patients affected by acute leukaemia

Vincenzo Triggiani 1 , Edoardo Guastamacchia 1 , Vincenzo Liso 2 , Giorgina Specchia 2 , Francesco Resta 3 , Carlo Sabbà 3 , Brunella Licchelli 1 & Emilio Tafaro 1


1Endocrinology, University of Bari, Bari, Italy; 2Ematology, University of Bari, Bari, Italy; 3Internal Medicine, University of Bari, Bari, Italy.


Aim: Aim of the study was the evaluation of the effects of chemotherapy on insulin secretion and insulin sensitivity in patients affected by acute leukaemia.

Materials and methods: Thirty-two non-diabetic patients (17 male, 15 female; age 51.1±17.4, range 16–76 years; BMI=25.1±3.7, range 18.4–32.8 kg/m2; 6=18% with a family history of diabetes mellitus) affected by acute leukaemia, 4 LLA (12.5%) and 28 LMA (87.5%), have been submitted to chemotherapy (different combination of mitoxantrone, cytarabine, vincristin, doxorubicin, etoposide and prednisone). Fasting glycaemia, insulin (IRI) and C-peptide have been evaluated before and after chemotherapy as well as HbA1c. Indices of beta cells function and insulin resistance have been calculated.

Results: The results are reported in the Table (P=NS).

Conclusion: All patients showed a basal condition of impaired fasting glucose, hyperglycaemia being frequently observed in critically-ill patients. Preliminary results of our study, however, show that chemotherapy does not influence measures of glycaemic control in non-diabetic patients affected by LLA and LMA.

FG (mmol/l)IRI (mU/l)C-pep (mcg/l)HbA1c (%)Glyc/Ins (mmol/mU)HOMA-IRHOMA β cell function
Pre-chemot.6.5±0.319.6±2.95.2±0.75.0±0.80.50±0.346.0±4.8148±115
Post-chemot.6.5±0.418.5±1.84.6±0.75.0±0.40.41±0.225.8±4.2130±66

Article tools

My recent searches

No recent searches.